AI external control arms
De-risk early-stage clinical trials
Owkin's external control arms increase the probability of success of your trial by providing early efficacy information
Question
How do we improve efficacy information in early-stage trials?
Providing a comparator arm in single arm phase I/II trials prevents late stage trial failures.
By increasing scientific and clinical accuracy, we help biopharma improve investor and regulatory perception of their assets.
Owkin’s solution
AI external control arms
Owkin's AI external control arms provide early estimates of efficacy for single-arm phase I/II clinical trials to reduce phase II/III uncertainty.
Methodology
Click
1
phase I/II single arm trial data
Extract key information on inclusion criteria and important patient clinical data
Step 1
Analyze
single arm trial data
Click
2
for external multimodal data
Accurately matching the trial population with the disease and standard of care
Step 2
Data hunt
for external multimodal data
Click
3
To train a model to predict treatment effect based on propensity score, G-computation or DDML
Step 3
State-of-the-art ML
to train a model
Click
Output
between patient outcome and predicted outcome
Improved efficacy analysis
Output
Comparison
between outcomes
How does Owkin's external control arms increase the probability of success of clinical trials? [02:03]
AI External Control Arms
Why Owkin?
Multimodal data access
We access hard-to-find data to accurately match your inclusion criteria.
AI & scientific expertise
Renowned AI expertise with # published papers in leading journals, two strategic alliances with leading biopharma companies, and AI digital pathology diagnostics.
Federated technologies
We can federate siloed data to increase the size and diversity of datasets.
Regulatory
Continued conversations with regulators plus ongoing projects with Pharma that include regulatory discussions.